Variables | n = 58 |
---|---|
No. (%) | |
Sex | |
 Male | 45 (78%) |
 Female | 13 (22%) |
Age (years) (Median, Range) | 66 (38–82) |
ECOG performance status | |
 0 | 8 (14%) |
 1 | 36 (62%) |
 2 | 12 (21%) |
 3 | 2 (3%) |
Disease status | |
 Metastatic | 43 (74%) |
 Relapsed | 15 (26%) |
Primary site | |
 Gastric | 49 (84%) |
 Esophagogastric junction | 9 (16%) |
Histological type | |
 Intestinal type | 34 (59%) |
 Diffuse type | 24 (41%) |
HER-2 status | |
 Positive | 13 (22%) |
Site of metastases | |
 Lymph nodes | 41 (72%) |
 Peritoneum | 27 (47%) |
 Liver | 20 (34%) |
 Lung | 12 (21%) |
 Bone | 9 (16%) |
 Other | 7 (12%) |
Organs with metastasis | |
 1 | 17 (29%) |
 2 | 24 (42%) |
 3 | 13 (22%) |
  ≥ 4 | 4 (7%) |
Previous treatment regimens | |
 2 | 35 (60%) |
 3 | 18 (31%) |
  ≥ 4 | 5 (9%) |
Previous therapies | |
 Pyrimidine analogs | 56 (97%) |
 Platinum | 50 (86%) |
 Taxane | 55 (95%) |
 Ramucirumab | 48 (83%) |
 Trastuzumab | 11 (19%) |
 Irinotecan | 16 (28%) |
Treatment period before nivolumab (months) | 14.9 (4.9–64.6) |
Immune-related adverse events | |
 Positive | 10 (17%) |